Clinical Trial Detail

NCT ID NCT02113813
Title A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications

lung non-small cell carcinoma

Therapies

Naquotinib

Age Groups: adult

No variant requirements are available.